Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
Citation
Burkill , S , Porsbjerg , C M , Bourdin , A , Tran , T N , Martin , N , Katial , R , Barker , P , Wechsler , M E , Maspero , J F , Bosnic-Anticevich , S , Chung , L P , Katsoulotos , G , Christoff , G , Popov , T A , Sadatsafavi , M , Torres-Duque , C A , Ulrik , C , Assing , K D , Hansen , S , Altraja , A , Lehtimäki , L A , Papadopoulos , N G , Kostikas , K , Salvi , S , Costello , R W , Puggioni , F , Iwanaga , T , Rhee , C K , Al-Ahmad , M , Larenas-Linnemann , D , Fonseca , J A , Amaral , R , Al-Lehebi , R , Perez de Llano , L , Kirenga , B , Tsai , M-J , Mahboub , B , Pfeffer , P E , Henley , W , Liu , Y , Lyu , J , Goh , C , Uthaman , T , Price , D & ISAR IGNITE 2022 , ' Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients ' , European Respiratory Journal , vol. 60 , no. 66 , 3305 . https://doi.org/10.1183/13993003.congress-2022.3305